Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 27 ... of substances which are known to bind to the estrogen receptor (ER) and antagonize the androgen receptor (AR). Short-chain petrogenic alkylphenols have been identified as responsible ...
2009 NOV 23 ... Pipeline Updates Toremifene 80 mg to reduce fractures in men with prostate cancer on androgen deprivation therapy (ADT): In October 2009, GTx received a Complete Response Letter from ...
2009 NOV 23 ... types of tumors. The present study was undertaken to evaluate the effects of BBI on androgen-sensitive/dependent prostate cancers using a human prostate cancer cell (LNCaP) and the ...
2009 NOV 18 ... from fetal testis dysfunction during a critical developmental period involving reduced androgen production/action. The recent increase in TDS prevalence suggests ...
2009 NOV 23 ... According to a study from the United States, "Androgen deprivation therapy for prostate cancer is associated with osteoporosis and increased ...
2009 NOV 23 ... in the journal Cancer Causes & Control report. "Prostate cancer (PC), an androgen sensitive tumor with a long natural history, may allow insights into this putative ...
2009 NOV 26 ... the present study, we assessed the effects of piceatannol on the growth of androgen-insensitive DU145 prostate cancer cells at concentrations of 1-10 mu mol/L. Piceatannol ...
2009 NOV 23 ... the United States, "Treatments for advanced prostate cancer (CaP) typically involve androgen deprivation therapy. However, most patients eventually develop castration-resistant CaP ...
2009 NOV 23 ... After 36 to 72-hour culture morphological, histological, proliferation, apoptosis, androgen signaling and activating transcription factor 3 analyses were done. The physiological ...
2009 NOV 23 ... these enzymes, histone deacetylase 6 (HDAC6), influences the acetylation state of a key androgen receptor (AR) chaperone, HSP90. AR is the central signaling pathway in prostate cancer, ...
2009 NOV 23 ... "We also determined whether DHEA effects are mediated by estrogen and androgen receptors. Proliferation of C33A (HPV-negative), CASKI (HPV16-positive) and HeLa ...
2009 NOV 24 ... published their study in Molecules and Cells (Insulin-like growth factor-I induces androgen receptor activation in differentiating C2C12 skeletal muscle cells. Molecules and Cells, ...
2009 NOV 23 ... by stereotactic biopsy. Diagnosis. DCIS in a male BRCA2 mutation carrier undergoing androgen deprivation therapy for prostate cancer. Management. The patient was treated with ...
2009 NOV 23 ... (REE) and Fox], SHBG, and thyroid binding globulin (TBG) as markers of excessive hepatic androgen exposure, were measured at the end of each treatment period. When compared to the ...
2009 NOV 23 ... According to recent research from the United States, "The profound hypogonadism due to androgen deprivation therapy for prostate cancer results in complications such as sexual ...
2009 NOV 23 ... 'Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy.' According to recent research published in the Journal of General ...
2009 NOV 24 ... "This study tested the hypothesis that the estrogen receptor (ESR) pathway, androgen receptor (AR) pathway, or both mediate estrogen-induced developmental penile disorders. ...
2009 NOV 23 ... novel mechanism of action acting in three distinct ways to treat prostate cancer: as an androgen receptor antagonist, as a CYP17 lyase inhibitor and by decreasing overall...
